Public-private partnerships in transplant drug development.

Autor: Albrecht R; Center for Drug Evaluation Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD., Papadopoulos EJ; Center for Drug Evaluation Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD., Campbell M; Center for Drug Evaluation Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD., Daniels S; Center for Drug Evaluation Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD., Kluetz PG; Oncology Center of Excellence Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD., Parekh A; Center for Drug Evaluation Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD., Wang Y; Center for Drug Evaluation Silver Spring, U.S. Food and Drug Administration, Silver Spring, MD.
Jazyk: angličtina
Zdroj: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2020 Feb; Vol. 20 (2), pp. 377-381. Date of Electronic Publication: 2019 Oct 30.
DOI: 10.1111/ajt.15604
Abstrakt: The Transplant Therapeutics Consortium (TTC), a public-private partnership (PPP) led by the Critical Path Institute (C-Path), recently published a whitepaper titled "The Importance of Drug Safety and Tolerability in the Development of New Immunosuppressive Therapy for Transplant Recipients" by Stegall et al in the American Journal of Transplantation. As staff members of the Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs and Office of Translational Science, and the Oncology Center of Excellence, we would like to provide our perspective on the TTCs efforts and the whitepaper.
(Published 2019. This article is a U.S. Government work and is in the public domain in the USA.)
Databáze: MEDLINE
Externí odkaz: